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Abstract
By dual labeling a targeting moiety with both nuclear and optical probes, the ability for noninvasive imaging and intra-
operative guidance may be possible. Herein, the ability to detect metastasis in an immunocompetent animal model of
human epidermal growth factor receptor 2 (HER-2)–positive cancer metastases using positron emission tomography
(PET) and near-infrared (NIR) fluorescence imaging is demonstrated. METHODS: (64Cu-DOTA)n-trastuzumab-
(IRDye800)mwas synthesized, characterized, and administered to female Balb/c mice subcutaneously inoculated with
highly metastatic 4T1.2neu/R breast cancer cells. (64Cu-DOTA)n-trastuzumab-(IRDye800)m (150 μg, 150 μCi,m = 2,
n=2)was administered through the tail vein atweeks 2 and 6 after implantation, andPET/computed tomography and
NIR fluorescence imaging were performed 24 hours later. Results were compared with the detection capabilities
of F-18 fluorodeoxyglucose (18FDG-PET). RESULTS: Primary tumors were visualized with 18FDG and (64Cu-DOTA)n-
trastuzumab-(IRDye800)m, but resultingmetastaseswere identified onlywith the dual-labeled imaging agent.
64Cu-PET
imaging detected lungmetastases, whereas ex vivo NIR fluorescence showed uptake in regions of lung, skin, skeletal
muscle, and lymph nodes, which corresponded with the presence of cancer cells as confirmed by histologic hema-
toxylin and eosin stains. In addition to detecting the agent in lymph nodes, the high signal-to-noise ratio fromNIR fluo-
rescence imaging enabled visualization of channels between the primary tumor and the axillary lymph nodes, suggesting
a lymphatic route for trafficking cancer cells. Because antibody clearance occurs through the liver, we could not distin-
guish between nonspecific uptake and liver metastases. CONCLUSION: (64Cu-DOTA)n-trastuzumab-(IRDye800)m may
be an effective diagnostic imaging agent for stagingHER-2–positive breast cancer patients and intraoperative resection.
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Introduction
Molecular imaging with target-specific moieties conjugated to optical
and nuclear reporters enables visualization of disease markers using
noninvasive techniques, whereas optical reporters can additionally
provide information for image-guided surgical procedures. Previously,
we and others have synthesized and characterized dual-labeled peptide
and antibody-based imaging agents in subcutaneous xenograft animal
models [1–13]. In two of these studies [3,14], optical and nuclear
imaging showed comparable tumor-to-muscle ratios (TMRs) after
intravenous administration of a dual-labeled agent, whereas near-
infrared (NIR) fluorescence optical imaging provided a significantly
higher signal-to-noise ratio than gamma imaging. In this study, we de-
signed a positron emission tomography (PET)/NIR imaging agent—
(64Cu-DOTA)n-trastuzumab-(IRDye800)m—which consists of an
antibody (trastuzumab) dual labeled with a beta emitter (Cu-64) for
PET imaging and a NIR dye (IRDye 800CW) to enable fluorescence
imaging of metastatic lesions overexpressing the human epidermal
growth factor receptor 2 (HER-2). We used a syngeneic mouse model
of an orthotopic mammary fat pad implantation, which exhibits
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metastases to organs similar to those affected in late-stage breast cancer.
We used this model to test the ability of the dual-labeled imaging agent
to detect metastases in sites distant from the primary tumor.
HER-2 is overexpressed because of gene amplification in approx-
imately 20% to 30% of breast cancer patients, often leading to poor
prognosis [15]. HER-2 is predominantly conserved during metastases
[16–19], making it a potential diagnostic biomarker. Trastuzumab
(Herceptin; Genentech, Inc, San Francisco, CA) is a humanized anti–
HER-2 antibody approved as a clinical therapeutic [20]. Trastuzumab
has been labeled by numerous investigators to generate imaging agents
with applications including but not limited to nuclear, optical, and
multimodal imaging (see TableW1). Yet to date, preclinical in vivo char-
acterization of its use as an imaging agent has predominantly focused on
subcutaneous tumor models using athymic mice.
Although the xenograft animal model is well established in cancer
research to provide information regarding the interaction between the
exogenously administered agent and the cancer cells in vivo, subcuta-
neous implantation of cancer cells neither realistically reproduces the
microenvironment around the tumor region nor enables determina-
tion of whether the imaging agent can detect metastases in deep tissue
organs. Xenograft models can approximate primary tumor growth in
mice, but murine tumor models with normal immune function may
be better suited to demonstrate detection of metastases. In this study,
we use a syngeneic mouse model in which HER-2 expressing mam-
mary cancer cells are introduced orthotopically into the mammary
fat pad to mimic late-stage human breast cancer metastases. We have
used this animal model to test the ability of the dual-labeled imaging
agent to detect metastases in sites distant from the primary tumor and
to compare to the clinical criterion standard of 18FDG-PET.
Materials and Methods
Wepurchased trastuzumab for research purposes at the hospital pharmacy
and used it before the date of expiration. Trastuzumab was stored at 4°C.
IRDye 800CWwas purchased from LI-COR Biosciences (Lincoln, NB)
and p-SCN-Bn-DOTA was purchased from Macrocyclics (Dallas, TX).
Synthesis of (DOTA)n-Trastuzumab-(IRDye800)m
Trastuzumab was conjugated with p-SCN-Bn-DOTA using a pre-
viously reported protocol with slight modifications [21]. In brief,
trastuzumab was dissolved in HEPES buffer (0.1 M, pH 8.5) at a con-
centration of 10 mg/ml and mixed with 20-molar excess of p-SCN-Bn-
DOTA (25 mg/ml) dissolved in ethanol. The reaction mixture was
incubated at 4°C overnight. Purification of (DOTA)n-trastuzumab from
excess chelator was achieved by using Zeba desalting columns (Pierce
Biotechnology, Rockford, IL) with PBS in the mobile phase. Final con-
centration was measured based on UVabsorbance at 280 nm using spec-
trophotometric analysis (model DU-800 instrument; Beckman Coulter,
Brea, CA). (DOTA)n-trastuzumab (5 mg/ml) was then reacted with
IRDye 800CW (30 μg/mg protein) dissolved in dimethyl sulfoxide
(50 μl/mg dye) at 4°C for 2 to 3 hours. (DOTA)n-trastuzumab-
(IRDye800)m was purified from free dye using Zeba desalting columns.
Radiolabeling of (DOTA)n-Trastuzumab-(IRDye800)m
64Cu was obtained from Washington University Medical School
(St Louis, MO) and supplied at high specific activity as 64CuCl2 in
0.1 MHCl. For radiolabeling, 64CuCl2 was diluted in ammonium ac-
etate buffer (0.2 M, pH 5.5) at 50 mCi/ml and added to (DOTA)n-
trastuzumab-(IRDye800)m. The reaction mixture was incubated at
50°C for 1 hour. (64Cu-DOTA)n-trastuzumab-(IRDye800)m was pu-
rified with PBS as the mobile phase using Zeba desalting columns, and
radiolabeling yield was calculated using ITLC.
Determination of the Number of DOTA and IRDye800
Molecules per Trastuzumab Antibody
The average number of DOTA molecules per trastuzumab was es-
timated using a protocol previously described [22]. In brief, 64CuCl2
was mixed with a defined amount of nonradioactive CuCl2 carrier
(80-fold excess of (DOTA)n-trastuzumab-(IRDye800)m) and added
to 50 μg of (DOTA)n-trastuzumab-(IRDye800)m in a total volume of
100 μl of 0.2 M sodium acetate buffer. The reaction mixture was incu-
bated at 50°C for 1 hour. (64Cu-DOTA)n-trastuzumab-(IRDye800)m
was purified using the Zeba desalting column, and radiolabeling
yield was calculated. The number of DOTAmolecules per trastuzumab
(n) was calculated as follows:
ðnÞ = moles Cu2+  × yield =moles of DOTAð Þn  trastuzumab
 IRDye800ð Þm
The IRDye800 to trastuzumab ratio (m) is estimated using the absor-
bance measurements of the dye and protein at 778 and 280 nm, respec-
tively, as described by the labeling protocol from LI-COR Biosciences.
A correction factor of 3% was subtracted from the measurement at
280 nm because of dye contribution.
Cell Lines
Cell lines used in this study include human SKBr3 andMDA-MB-231
and murine 4T1.2, 4T1.2neu, 4T1.2R, and 4T1.2neu/R breast cancer
cells. SKBr3 cells express high levels of HER-2, whereas MDA-MB-
231 cells express negligible amounts of HER-2. SKBr3 and MDA-
MB-231 cell lines were obtained fromAmerican Type Culture Collection
(Manassas, VA). 4T1.2 is a subline of breast cancer cells derived from
spontaneous carcinoma in a Balb/cfC3H mouse [23]. Because HER-2
is highly conserved across species, we used 4T1.2neu cells, which were
established by transducing the rat homolog of HER-2, neu, into 4T1.2
breast cancer cells with a retroviral vector, pFB-Neu-Neo [24]. Both
4T1.2 and 4T1.2neu were generously provided by Zhaoyang You (Uni-
versity of Pittsburg School of Medicine, Pittsburgh, PA). We transfected
both these cell lines with p-DsRedExpress-N1 (Clontech, Mountain
View, CA) to generate 4T1.2R and 4T1.2neu/R which were selected
by flow cytometry using a Becton-Dickinson FACS Aria flow cytom-
eter (BD Biosciences, San Jose, CA). The DsRed-expressing cells were
cultured in Dulbecco’s minimal essential medium F-12 with 10% fetal
bovine serum, 1% antibiotic-antimycotic solution, and 1mg/ml of G418
in a humidified incubator maintained at 37°C with 5% CO2.
In Vitro Microscopy
Cells were grown on coverslips in a 24-well dish. When cells reached
90% confluence, cells were washed and blocked with Odyssey Blocking
Buffer (LI-COR Biosciences) for 1 hour. Cells were then incubated with
primary mouse anti–HER-2 antibodies or (Cu-DOTA)n-trastuzumab-
(IRDye800)m diluted in Odyssey Blocking Buffer for 1 hour at 4°C.
Cells were washed and stained with secondary antibodies, goat anti-
mouse AlexaFluor 488 or mouse antihuman fluorescein isothiocyanate,
respectively, for 30 minutes at 4°C. After this incubation period, cells
were washed again, and the cover slips were placed on a glass slide with
mounting medium containing 4′-6-Diamidino-2-phenylindole nuclear
stain (Vectashield; Vector Laboratories, Burlingame, CA).
All images were acquired using a Leica DFC350FX microscope
(Leica Microsystems, Inc, Bannockburn, IL) connected to a computer.
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Images were processed using Leica Application Suite software or Image J
(National Institutes of Health, Bethesda, MD).
In-cell Western Blot
4T1.2 and 4T1.2neu cells were seeded in a 96-well plate and grown
overnight. Cells were fixed and blocked using Odyssey Blocking Buffer
(LI-COR Biosciences) for 1 hour at room temperature. Mouse antirat
HER-2/neu primary antibody (Calbiochem, La Jolla, CA)was diluted in
blocking buffer at a concentration of 5 μg/ml and added to the cells to
incubate for 2.5 hours at room temperature. Cells were washed with
Tris-buffered saline and Tween 20 and IRDye 800CW–labeled goat
antimouse IgG secondary antibody (LI-COR Biosciences) was added
to cells at a dilution of 1:1000. For normalization of cell number,
DRAQ5 (LI-COR Biosciences) diluted at 1:5000 was also added to
the cells and allowed to incubate for 1 hour. After repeated washing,
the wells were allowed to dry and fluorescence imaging was performed
on the Odyssey infrared imaging system (LI-COR Biosciences) using
the 800-nm channel to measure HER-2 expression and the 700-nm
channel to normalize for cell count using fluorescence from DRAQ5.
Animal Model
Female Balb/c mice (8 weeks old; Charles River, Wilmington, MA)
were housed and maintained in a specific pathogen-free colony at the
Institute of Molecular Medicine, UT-Health Science Center, and were
fed standard chow diet. The facility is accredited by the American Asso-
ciation for Laboratory Animal Care, and all experiments were performed
in accordance with the guidelines of UT-Health Science Center Institu-
tional Animal Care and Use Committee. Animals were subcutaneously
injected with 4T1.2neu/R (1-2 × 106 in 20 μl) into the fourth mammary
fat pad. Initial tumor growth was monitored with DsRed fluorescence
imaging. Before imaging, mice were shaved, and residual fur was removed
using a depilatory agent. 18FDG (200-250 μCi) or (64Cu-DOTA)n-
trastuzumab-(IRDye800)m (150 μg, 150 μCi, n = 2, m = 2) were in-
jected intravenously at week 2 in 4T1.2neu/R (N = 5) or at week 6
in 4T1.2R (N = 6), 4T1.2neu/R (N = 6) and non–tumor-bearing
(N = 3) mice, for subsequent microPET/computed tomography (CT)
and NIR fluorescence imaging. 18FDG was injected first, and PET/CT
imaging was performed. (64Cu-DOTA)n-trastuzumab-(IRDye800)m-
was injected after 10 half-lives of F-18 radioactive decay, followed
by NIR fluorescence imaging and PET/CT approximately 24 hours
later. The imaging time point was determined based on the radioactive
half-life of 64Cu (t1/2 = 12.7 hours), although no significant increase in
tumor uptake has been shown with NIR fluorescence imaging at time
points greater than 24 hours [10]. After in vivo imaging techniques,
mice were euthanized, and select organs were harvested for ex vivo
NIR fluorescence imaging. For further histopathologic analysis, tissue
samples were placed in 10% formalin overnight and sent to the Cen-
ter for Comparative Medicine Pathology Core (Baylor College of
Medicine, TX) before undergoing routine histologic processing, sec-
tioning, and hematoxylin and eosin (H&E) staining.
In Vivo Fluorescence Imaging
NIR and DsRed fluorescence images were acquired using custom-built
fluorescence imaging systems [10]. Briefly, a field of view was illuminated
with 785 or 568 nm of light from a laser diode (500 mW; Intense Ltd,
North Brunswick, NJ) or air-cooled argon-krypton laser (Model 643R-
AP-A01, 200 mW; Melles Griot, Carlsbad, CA), respectively, outfitted
with a convex lens and diffuser to create a uniform excitation field. The
fluorescence was collected through holographic (model HNPF-785.0-
2.0 for NIR and model 568.2-6 for DsRed; Kaiser Optical Systems,
Inc, Ann Arbor, MI) and interference (model 830.0-2.0 for NIR, Image
Quality [Andover Corp, Salem,NH] andmodelHQ610/60M forDsRed
[Chroma Technology Corp, Bellows Falls, VT]) filters placed before a
Nikon camera lens (Nikkor 28 mm; Nikon, Tokyo, Japan). The images
were finally captured by an electron-multiplying charge-coupled device
camera (PhotonMax 512; Princeton Instruments, Princeton, NJ) with
200 to 400 milliseconds of integration time. For acquisition of white-light
images, the optical filters were removed, and a low-power lamp illumi-
nated the subject. Image acquisition was accomplished by V++ software
(Aukland, New Zealand).
Whole-body fluorescence images were acquired 24 hours after intra-
venous administration of (64Cu-DOTA)n-trastuzumab-(IRDye800)m
(150 μg, 150 μCi). On sacrifice, ex vivo fluorescence imaging of har-
vested organs was also performed.
MicroPET/CT Imaging
In vivo small animal PET/CT imaging studies were performed using
an INVEON dedicated PET docked with an INVEON multimodal-
ity CT (Siemens Medical Solutions, Knoxville, TN). The CT imaging
parameters were an x-ray voltage of 80 kV with an anode current of
500 μA and an exposure time of 260 milliseconds of each of the
120 rotation steps over the total rotation of 220° at low system mag-
nification. After CT imaging, PETemission scans were performed on
separate days with acquisition times of 5 (18F) and 10 minutes (64Cu).
PETand CT images were reconstructed using two-dimensional filtered
back-projection and a Feldkamp cone-beam algorithmwith a ramp filter
cutoff at the Nyquist frequency, respectively. PETand CT image fusion
and image analysis were performed using ASIPro, Inveon Research
Workplace (Siemens Preclinical Solutions) and AMIRA (version 3.1;
Konrad-Zuse-Zentrum fur Informationstechnik, Berlin, Germany).
Statistical Analysis
All data were analyzed using one-way analysis of variance, the sig-
nificance level was set at 0.05, and all quantitative data are represented
as mean ± SD. To determine TMR or lung-to-muscle ratio (LMR)
from NIR fluorescence images, a region-of-interest was drawn around
the tumor, lung, or muscle region, and the total fluorescence signal
intensity associated with the region was computed. TMR or LMR
from NIR fluorescence images was calculated as follows:
TMR or LMR = ðsum of f luorescence counts in tumor or lung
region = number of pixelsÞ= ðsum of f luorescence counts in
muscle region = number of pixelsÞ
To calculate TMR from PET images, tumor standardized uptake value
(SUV) and the contralateral muscle SUV were computed using the
Inveon Research Workplace (Siemens Preclinical Solutions). TMR
calculations were performed as follows:
TMR = Tumor SUV =Muscle SUV
Results
Characterization of ( 64Cu-DOTA)n-Trastuzumab-(IRDye800)m
Trastuzumab was conjugated to p-SCN-Bn-DOTA and IRDye
800CW, resulting in approximately 2.4 ± 0.2 DOTA molecules per
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Figure 1. Fluorescencemicroscopy imaging shows significant binding of (Cu-DOTA)n-trastuzumab-(IRDye800)m to HER-2–overexpressing
SKBr3 cells in comparison to low HER-2 expressing MDA-MB-231 cells.
Figure 2. 4T1.2neu cells have an elevated level of HER-2/neu receptor density comparedwith 4T1.2 breast cancer cells. (A) In-cell Western
blot shows fluorescence signal intensity after HER-2/neu staining (top panel). Cells were normalized using DRAQ5 nuclear staining (middle
panel), whereas the compositemerged signals are shown in the bottom panel. (B) Quantification ofmean fluorescence signal intensity. (C)
Fluorescence microscopy imaging shows significantly higher binding of (Cu-DOTA)n-trastuzumab-(IRDye800)m in 4T1.2neu/R cells com-
pared with 4T1.2/R.
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antibody (n). The IRDye800 to trastuzumab ratio was 2.2 ± 0.3 (m).
The yield of (DOTA)n-trastuzumab-(IRDye800)m after purification
was greater than 85%. Radiolabeling yield with Cu-64 was greater than
90%. Immunoreactivity as determined by the cell-binding assay de-
scribed by Lindmo et al. [25] was determined to be 76.4% ± 3.6%.
In Vitro Characterization
Figure 1 illustrates binding of (Cu-DOTA)n-trastuzumab-(IRDye800)m
in SKBr3 (HER-2–overexpressing) and MDA-MB-231 (low expressors
of HER-2) cells as visualized through fluorescence microscopy. The
imaging agent binds with high affinity to SKBr3 cells, whereas there
is negligible binding in MDA-MB-231 cells. Also, the binding seems
to be extracellular, which is consistent with the location of the trans-
membrane HER-2 receptors. The dual-labeled imaging agent bound
to greater than 90% of SKBr3 cells, as determined by NIR FACS.
Figure 2A represents an in-cell Western blot to quantify the difference
in HER-2 levels between 4T1.2 and 4T1.2neu cells. The top panel in
Figure 2A shows the fluorescence signal from HER-2/neu staining in
cells, themiddle panel shows the DRAQ5 nuclear staining for normaliza-
tion with cell number, whereas the bottom panel shows the combined
fluorescence signal. The quantitative results are depicted graphically in Fig-
ure 2B. Figure 2C compares the binding of (Cu-DOTA)n-trastuzumab-
(IRDye800)m in DsRed-transfected 4T1.2R and 4T1.2neu/R cells.
Both cell lines express DsRed as illustrated, but 4T1.2neu/R has a sig-
nificantly higher fluorescence because of binding of the dual-labeled
imaging agent compared with 4T1.2R.
In Vivo Characterization
Because DsRed expression was lost with tumor progression, DsRed
fluorescence imaging was conducted to assess inoculation and initial
growth. DsRed fluorescence imaging of a shaved Balb/c mouse with
a subcutaneous 4T1.2neu/R tumor confirms the location of the tumor
(Figure 3A). The corresponding NIR fluorescence image acquired
24 hours after (64Cu-DOTA)n-trastuzumab-(IRDye800)m adminis-
tration is shown in Figure 3B. PET signal fused with CT after
(64Cu-DOTA)n-trastuzumab-(IRDye800)m and
18FDG administra-
tion revealed significant uptake within the tumor compared with the
muscle region. Representative coronal sections are represented in Fig-
ure 3,C andD, with crosshairs indicating tumor location. In addition to
tumor uptake, the dual-labeled imaging agent accumulates within the
liver, as seen in both PETandNIR fluorescence images. The nonspecific
liver uptake may be attributed to the interaction of the Fc portion of the
antibody with hepatocytes and is consistent with the site of antibody
degradation and clearance.
Tumor uptake after 18FDG and (64Cu-DOTA)n-trastuzumab-
(IRDye800)m administration shows comparable results as observed by
Figure 3. DsRed fluorescence imaging (A) shows the location of 4T1.2neu/R primary tumor in Balb/c mice, 2 weeks after subcutaneous
inoculation into the mammary pad. NIR fluorescence (B) and PET/CT (C) imaging performed 24 hours after intravenous administration of
(64Cu-DOTA)n-trastuzumab-(IRDye800)m shows uptakewithin the tumor. PET/CT images acquired 2 hours after administration of
18FDG (D)
also show tumor uptake. TMR determined from PET (18F, 64Cu) and NIR fluorescence imaging shows no statistical significance (P> .1) (E)
and indicate that (64Cu-DOTA)n-trastuzumab-(IRDye800)m and
18FDG are comparable with each other in detecting subcutaneous tumors.
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PET imaging, but differences were observed in the in vivo distribution
between the two imaging agents. In vivo TMRs between 18FDG-PET,
64Cu-PET, and NIR imaging ranged from 2.09 ± 0.37, 2.21 ± 0.40,
and 2.81 ± 0.70, respectively (Figure 3E). No statistically significant dif-
ferences (P > .1) between the TMR were observed between the modal-
ities, indicating that the diagnostic capabilities of the molecularly
specific dual-labeled imaging agent—(64Cu-DOTA)n-trastuzumab-
(IRDye800)m—are similar to those of clinically approved but non-
specific 18FDG for detecting primary tumors.
Metastases in the 4T1.2 animal model are known to occur by 5 to
6 weeks [23]. To assess the imaging capabilities of (64Cu-DOTA)n-
trastuzumab-(IRDye800)m in detecting HER-2–overexpressing meta-
static lesions arising from the primary tumor, we acquired PET/CT
and NIR fluorescence images after administration of the dual-labeled
imaging agent in 4T1.2neu/R tumor-bearing Balb/c mice and com-
pared the results with 18FDG. We also compared uptake between non-
tumor control, 4T1.2R, and 4T1.2neu/R tumor-bearing mice injected
with (64Cu-DOTA)n-trastuzumab-(IRDye800)m and
18FDG. Figure 4
shows NIR fluorescence, 64Cu-PET, and 18FDG-PET images from a
representative mouse from each group. All mice showed nonspecific up-
take of the dual-labeled imaging agent in the liver. The primary tumor
region of the 4T1.2R tumor-bearing mice showed some uptake of the
imaging agent, but there was significantly higher binding within the
4T1.2neu/R tumors as confirmed ex vivo. Nevertheless, because
18FDG is molecularly nonspecific, it did not differentiate between the
two tumor types, and we were able to detect both 4T1.2R and
4T1.2neu/R tumors. Although we were able to visualize the primary tu-
mor with all modalities, 18FDG-PETwas not effective in detecting me-
tastases. In contrast, we were able to detect multiple sites of 4T1.2neu/R
metastases with the molecularly specific dual-labeled (64Cu-DOTA)n-
trastuzumab-(IRDye800)m. Owing to intrinsic differences between
PET and NIR imaging capabilities, the metastatic lesions identified
Figure 4. Comparison of (64Cu-DOTA)n-trastuzumab-(IRDye800)m and
18FDG distribution on Balb/c mice subcutaneously inoculated with
4T1.2neu/R (A-E), 4T1.2/R (F-J), and non–tumor-bearing (K-O) mice. NIR fluorescence (A) and PET imaging with Cu-64 (B) and 18FDG (C)
showed uptake of imaging agents within the primary 4T1.2neu/R tumor. In mice inoculated with 4T1.2/R tumors, there was a reduction in
accumulation of the dual-labeled agentwithin the primary tumor as shownwithNIR fluorescence (F) and 64Cu-PET (G) imaging, but 18F-PET
detected the 4T1.2/R tumor (H). Compared with 4T1.2/R (I, J) and non–tumor-bearing mice (M, O), PET/CT coronal section of 4T1.2neu/R
tumor-bearing mice shows detection of lung metastases with the dual-labeled (64Cu-DOTA)n-trastuzumab-(IRDye800)m (D), whereas
18FDG was not successful in detecting metastases (E).
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through both modalities complemented each other. Lung metastases
were clearly visualized noninvasively in vivo with 64Cu-PET (Figure 4,
B and D) in 4T1.2neu/R tumor-bearing mice, whereas limitations
associated with scatter in deep tissue prevented detection with planar
in-vivo NIR fluorescence imaging. Figure 4, D and E , I and J , and
N and O, shows PET/CT sections acquired after (64Cu-DOTA)n-
trastuzumab-(IRDye800)m and
18FDG administration in representa-
tive 4T1.2neu/R, 4T1.2/R, and non–tumor-bearing mice, respectively.
The crosshairs indicate lung location. 18FDG-PET from both the
tumor- and non–tumor-bearing mouse shows no accumulation within
the lung. In contrast, 64Cu-PET shows significant accumulation of the
dual-labeled imaging agent within the lung region of a 4T1.2neu/R
tumor-bearing mouse compared with the 4T1.2R and nontumor control.
The high spatial resolution achieved using NIR fluorescence imag-
ing enabled us to detect metastatic lesions (∼2 mm diameter) close to
the skin (Figure 5, A and B), whereas PET imaging could not identify
them. Optical imaging enabled us to visualize trafficking of the imag-
ing agent from the primary tumor to proximal and distant lymph
nodes when we removed the skin to reveal themammary pad (Figure 5,
C through E ). This correlates with previous reports of lymphatic in-
volvement in tumor growth andmetastatic process of this animal model
[26]. When we performed whole skin dissection of the tumor-bearing
Figure 5. (64Cu-DOTA)n-trastuzumab-(IRDye800)m detected superficial skin metastases in Balb/c mice implanted with 4T1.2neu/R tumor
as visualized by NIR fluorescence imaging (A, B). Ex vivo NIR fluorescence imaging revealed trafficking of the dual-labeled (64Cu-DOTA)n-
trastuzumab-(IRDye800)m imaging agent from the primary tumor to distant lymph nodes (C-E).Whole-skin dissections showed accumulation
of the imaging agent within the tumor, mammary pad, lymph nodes, and metastatic sites within the skin (F-G). All images in this figure have
been acquired from the same mouse.
Translational Oncology Vol. 3, No. 5, 2010 Hybrid Imaging of Cancer Metastasis Sampath et al. 313
mouse, in addition to visualizing the primary tumor, we observed ac-
cumulation of the imaging agent in lymph nodes and sections of the
mammary pad. A representative photograph and NIR fluorescence
image of a whole skin dissection is represented in Figure 5, F and G ,
respectively. In addition to the primary tumor, the tumor-draining
lymph node (inguinal) is fluorescent and confirmed to be cancer-
positive from H&E histologic staining. The skin metastatic lesions
are also indicated.
We identified a total of 15 fluorescent lymph nodes from six tumor-
bearing mice used in this study and performed further investigation
using histologic staining. Only seven nodes were infiltrated by cancer
cells. However, extensive inflammation and presence of granulopoieisis
was observed in all the lymph nodes in addition to spleen and liver,
consistent with previous reports [26–29]. Although in vivo whole-
body NIR fluorescence imaging of (64Cu-DOTA)n-trastuzumab-
(IRDye800)m did not show accumulation within the lung, we were
able to confirm the presence of the imaging agent ex vivo on har-
vesting the organs after sacrifice (Figure 6A). Representative histologic
H&E staining of the 4T1.2neu/R primary tumor and lung, lymph
nodes, muscle, and skin metastases are shown in Figure 6, B to F.
We removed the skin of mice to reveal the mammary pad and
compared whole skin dissections (Figure 7, A–F ) within the three
groups of mice to assess the specificity of 64Cu-DOTA)n-trastuzumab-
(IRDye800)m binding in lymph nodes. The nontumor control mice
and the mice inoculated with 4T1.2/R did not show accumulation
of the imaging agent within the mammary pad or lymph nodes. In
Figure 6. (A) Ex vivoNIR fluorescence imaging of organs harvested 24 hours after administration of (64Cu-DOTA)n-trastuzumab-(IRDye800)m.
Compared with muscle, there is high uptake in tumor, lung, and organs involved in antibody degradation, namely liver and kidneys. Spleen
is enlarged because of the elevated levels of granulopoeisis and leukocytosis. Histologic H&E staining of representative primary 4T1.2neu
tumor (B) and lymph node with a metastatic tumor (C) are shown. Arrows indicate numerous neoplastic cells in the subcapsular sinus.
N indicates lymph node; T, tumor. Representative section of lung with a metastatic tumor (D) is shown with numerous neoplastic cells [T]
seen around a pulmonary blood vessel. Also indicated are numerous circulating neutrophils in the alveolar septa (arrows) and in the large
blood vessel [V]. L indicates alveolar space. We also observed skin (E) and skeletal muscle (F) metastases with arrows indicating numerous
neoplastic cells (T) separating individual muscle fibers. S indicates skin.
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contrast, mice with 4T1.2neu/R tumors showed an increased back-
ground fluorescence signal within the entire skin in addition to sections
of the mammary pad. Figure 7F shows another representative image
where trafficking of the imaging agent from the primary tumor and
its associated lymph node to the axillary region can be visualized.
We hypothesize that theNIR fluorescence signal fromwithin lymph
nodes and the mammary pad may be due to the interaction of the
antibody-based imaging agent with elevated levels of HER-2/neu an-
tigen expression as a result of the 4T1.2neu/R tumor.
The ex vivo NIR fluorescence LMR in 4T1.2neu/R tumor-bearing
mice (2.85 ± 0.67) was found to be statistically higher in comparison with
non–tumor-bearing mice (1.23 ± 0.15) with a P < .05 (Figure 7H ). The
large error bar found in the LMR in tumor-bearingmice can be due to the
variability in the extent of lung metastases within each mouse.
Ex vivo NIR fluorescence TMR estimated from 4T1.2neu/R tumors
(4.03 ± 0.57)was also found to be statistically higher than 4T1.2R tumors
(1.83 ± 0.33) (P < .05) as shown in Figure 7G . LMR of 4T1.2neu/R
tumor-bearing mice (2.85 ± 0.67) was found to be statistically higher
in comparison with 4T1.2/R (1.45 ± 0.19) and non–tumor-bearing
mice (1.23 ± 0.15) with a P < .05 (Figure 7H ).
Discussion
According to the National Cancer Institute, approximately 191,000
new cases of breast cancer and 41,000 deaths were reported in 2009.
Patient mortality and morbidity is often due to late-stage complications
that arise from progression of the disease to distant metastatic sites. In
breast cancer, the most common sites of metastases include lung, liver,
bone, and brain. Metastasis is a complex and multistep process where
the tumor cells have to detach from the primary tumor, enter the lym-
phatic or blood circulation, reach a distant site, attach, and proliferate.
Molecular imaging techniques have immense potential in enhancing
early stage diagnostics, monitoring treatment efficacy, and affecting
drug discovery.
The 4T1 animal model was originally isolated by Fred Miller et al.
[30] at the Karmanos Cancer Institute. By 6 weeks, 4T1 cells and sub-
clones have been shown tometastasize to various organs including lungs,
Figure 7. Comparison of ex vivoNIR fluorescence imaging ofwhole skin dissections between non–tumor-bearing (A, D), 4T1.2/R (B, E), and
4T1.2neu/R (C, F) tumor-bearing Balb/c mice 6 weeks after subcutaneous inoculation. TMR comparisons showed that there was signifi-
cantly higher binding in 4T1.2neu/R tumors (4.03 ± 0.57) compared with 4T1.2/R tumors (1.83 ± 0.33; P< .05) (G). Also, quantitative LMR
in 4T1.2neu/R tumor-bearing mice (2.85 ± 0.67) is significantly higher compared with 4T1.2/R (1.45 ± 0.19) and the non–tumor-bearing
mice (1.23 ± 0.15), P < .05.
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liver, and bone [23,26,31,32]. Although a number of investigators have
used cancer cell lines expressing reporters to visualize cancer migration
during metastases [33–39], very few studies have been performed
where an exogenous diagnostic agent is administered to detect metas-
tases within an animal model. In a recent report, Cao et al. [40] syn-
thesized 64Cu-DOTA-IL-18bp-Fc to assess the tumor-targeting
efficiency and pharmacokinetics in interleukin-18 binding protein–
sensitive cells using PET imaging in a lung metastases model. In the
present study, we have demonstrated the targeting capabilities of
(64Cu-DOTA)n-trastuzumab-(IRDye800)m in vitro using fluorescence
microscopy andwith an in vivo cancer model to assess uptake in primary
tumors and subsequent metastases after intravenous administration of
the imaging agent. Although there have been several studies using tras-
tuzumab labeled for imaging with nuclear, magnetic resonance imaging,
and optical techniques (see Table W1), this study is one of the first re-
ports to use it in a dual-labeled diagnostic imaging agent to identify dis-
tant organ metastases. Because molecular-specific optical and nuclear
probes have unique sets of advantages, combining modalities offers a
wider range of opportunities for early detection of disease. Deep tissue
penetration by radioactive isotopes enabled detection of lungmetastases,
whereasNIR fluorescence imaging provided information regarding lym-
phatic involvement. In addition to nonspecific radiocolloids used in the
clinic, molecular imaging approaches such as these can potentially en-
hance the accuracy of nodal staging, although human trials will have to
be conducted to confirm benefit.
Conclusions
Dual-labeled (64Cu-DOTA)n-trastuzumab-(IRDye800)m was tested for
molecular specificity inHER-2–overexpressing breast cancer cells as well
as in a relevant metastatic animal model to assess and confirm target-
ing in vitro and in vivo. Furthermore, we have compared the detection
capabilities of the imaging agent with 18FDG and have showed that
(64Cu-DOTA)n-trastuzumab-(IRDye800)m has greater sensitivity in
detection of metastases overexpressing HER-2.
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Table W1. Review of Preclinical Imaging Using Trastuzumab to Target HER-2.
Imaging Modality Imaging Agent In Vitro/In Vivo:
Cell Lines Used
Dose Route Reference
Nuclear medicine
PET 64Cu-DOTA-Herceptin In vivo (mice): BT-474,
MCF-7, MDA-MB-468
(s.c.)
4 MBq i.v. [41]
68Ga-DOTA-F(ab′)2 309 MBq
89Zr-trastuzumab In vivo (mice): SKOV3,
GLC4 (s.c.)
100 μg of trastuzumab,
1 MBq i.v. [42]
SPECT/CT 111In-DOTA-Fab4D5,
111In-DOTA-AB.Fab4D5
In vivo (mice): tumors
cells derived from
MMTV/HER-2
transgenic mice (s.c.)
4 mg/kg (300-500 μCi) i.v. [43]
25 MBq (30 μg) i.v. [44–46]
Scintigraphy
(whole body)
[99mTc]-HYNIC-trastuzumab Fab,
111In-trastuzumab Fab,
111In-DTPA-trastuzumab
In vivo (mice): BT474,
SK-OV-3 (s.c.)
3.7 MBq (30 μg)
In vivo (mice, humans) Mice: 450 ± 25 kBq (25 μg);
human: 100-150 MBq (5 mg)
i.v.
Scintillation counter
(tissue/cells)
111In-DOTA-Herceptin,
111In-DOTA-F(ab′)2,
111In-CHX-A -DTPA-Herceptin,
90Y-DTPA-Herceptin
In vivo (mice): BT474 (s.c.) 1.6 MBq i.v. [41]
In vitro: MCF-7, SKBr-3
Magnetic resonance
tomography
WSIO-Herceptin In vivo (mice): NIH3T6.7 (s.c.) 400 μg of Fe i.v. [47,48]
Biotinylated Herceptin with
streptavidin-SPIO microbeads
In vitro: MCF-7, MDA-MB-231,
AU-565 (gel phantoms)
2-50 × 1010 biotin/μl
Herceptin nanoparticles In vivo (mice): SKBr3, KB 20 μmol/kg i.v. [49]
Optoacoustic tomography Herceptin conjugated with gold
nanoparticles (MabNP)
In vitro: SKBR3, BT-474,
MDA-MB-231, and MCF-7
109 Mab/NP [50]
Optical imaging
Fluorescence imaging Cy5.5-labeled Herceptin In vitro: SK-BR-3,
L6 rat myoblasts
100 μg i.v. [51]
Herceptin-RhodG In vivo (mice): SK-BR-3,
PE/CA-PJ34 (s.c.)
50 μg in 200 μl of PBS i.v. [52]
Tra-Cy5.5 (SQ) In vivo (mice): 3T3/HER-2+,
Balb/3T3/HER-2− (s.c.)
50 μg/100 μl of PBS i.v. [53]
Tra-Alexa680(SQ)
Fluorescence quantum dots Trastuzumab-Qdots In vivo (mice): 3T3/HER-2+,
Balb/3T3/HER-2−
2 μM (100 μl), 5-6 μm
tissue sections stained with 10 nM
i.v. [54,55]
In vivo (mice), Ex vivo (tumor from mice):
KPL-4, MBA-MB-231 (s.c.)
Dual-labeled imaging
agents (nuclear
and optical)
(111In-DTPA)n-trastuzumab-(IRDye800)m In vitro: SKBr3 and MDA-MB-231 [10,14]
In vivo: SKBr3-luc (s.c.) 80-200 μg (70-200 μCi) i.v., i.d.
i.v. indicates intravenous; s.c., subcutaneous; i.d., intradermal.
